Skip to main content
News

Deka Biosciences Publishes New Data in Cell Reports Medicine, Announces Search for Combination Partners for DK210(EGFR)

By August 1, 2025No Comments

Germantown, MD — Deka Biosciences, a clinical-stage biotechnology company developing next-generation cytokine therapies for cancer and inflammatory disease, announced the publication of a peer-reviewed manuscript in Cell Reports Medicine highlighting the unique mechanism of action behind its lead Diakine™ oncology asset, DK210 (EGFR).

This newly published research reveals how DK210 (EGFR), a tri-specific fusion protein, delivers potent anti-tumor activity with a favorable safety profile. With dose-finding studies in patients now complete, Deka is actively seeking combination partners to explore therapeutic synergies with T cell engagers (TCEs).

Key Mechanistic Highlights:

  • Tumor Targeting: DK210 (EGFR) binds EGFR to localize and retain activity at the tumor site.
  • Cytokine Balancing: The fusion of IL-10 with IL-2 reduces inflammation-driven toxicities, such as cytokine release syndrome (CRS) and edema.
  • Immune Activation and Persistence: DK210 (EGFR) uncouples toxicity from immune activation, enabling persistent CD8+ T cell secretion of IFNγ, Granzyme B, and Perforin – critical elements of sustained anti-tumor response.

The full manuscript is available in Cell Reports Medicine, and a detailed overview of the mechanism, including visual data summaries, can be accessed at dekabiosciences.com/moa.

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.